

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: CHEMGENEX PHARMACEUTICALS LIMITED
ABN: 79 000 248 304

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Elmar Schnee
Date of last notice	1 April 2011

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect and direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Fully paid ordinary shares (ASX Code: CXS) are held by Merck Santé.
Date of change	11 May 2011
No. of securities held prior to change	1,925,960 fully paid ordinary shares (ASX Code: CXS) held indirectly; 40,000 fully paid ordinary shares (ASX Code: CXS) held directly; and 250,000 unlisted options exercisable at \$1.22 per option held directly;
Class	Fully paid ordinary shares
Number acquired	N/A
Number disposed	1,925,960 fully paid ordinary shares (ASX Code: CXS) held indirectly; and 40,000 fully paid ordinary shares (ASX Code: CXS) held directly.

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$1,376,172 (\$0.70 per fully paid ordinary share)
No. of securities held after change	250,000 unlisted options exercisable at \$1.22 per option held directly.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Acceptance of Share Offer and Listed Option Offer in accordance with terms and conditions of the Share Offer and Listed Option Offer outlined in the Bidder's Statement announced on 13 April 2011.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	



Date: 11 May 2011

Print name: James Campbell, Company Secretary

⁺ See chapter 19 for defined terms.